SCHEMBL18056914

SCHEMBL18056914

CCCCOc1nc(OCCCC)c2[nH]ccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 5/20 0.43
CCNB1 P14635 4/20 0.43
CDK2 P24941 4/20 0.43
CCNA2 P20248 3/20 0.43
CCNA1 P78396 3/20 0.43
PIN1 Q13526 1/20 0.43
CYP1A2 P05177 4/20 0.37
CYP3A4 P08684 3/20 0.37
CYP2D6 P10635 3/20 0.37
CYP2C9 P11712 3/20 0.37
CYP2C19 P33261 3/20 0.37
CYP19A1 P11511 2/20 0.37
TLR7 Q9NYK1 8/20 0.36
KDM4E B2RXH2 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MAPK1 P28482 2/20 0.35
TSHR P16473 2/20 0.35
HTT P42858 2/20 0.35
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20513056 0.84 TLR7 (0.47) TLR7
SCHEMBL4059711 0.72 MGMT (0.47) CDK1CCNB1CDK2CCNA2CCNA1
SCHEMBL18056913 0.71 CDK1 (0.42) CDK1CCNB1CDK2CCNA2CCNA1
SCHEMBL4062331 0.70 KDR (0.39) CYP1A2MAPK1TSHRPDPK1KDR
SCHEMBL598441 0.70 CYP2D6 (0.43) CDK1CCNB1CDK2CCNA2CCNA1
SCHEMBL21462266 0.66 TLR7 (0.42) CYP3A4CYP2D6TLR7
SCHEMBL9375291 0.66 CYP1A2 (0.42) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL28081599 0.66 CYP2D6 (0.39) CDK1CCNB1CDK2CCNA2CCNA1
SCHEMBL26174401 0.65 CDK1 (0.48) CDK1CCNB1CDK2CCNA2CCNA1
SCHEMBL899058 0.64 NR5A1 (0.43) CDK1CCNB1CDK2CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170014415-A1 THIENO- AND PYRROLOPYRIMIDINE ANALOGUES AS ANTICANCER AGENTS AND METHODS OF USE THEREOF UNIV MARYLAND (US) 2017-01-19 US disclosed
US-20160257696-A1 THIENO- AND PYRROLOPYRIMIDINE ANALOGUES AS ANTICANCER AGENTS AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE COUNTY 2016-09-08 US disclosed
US-9434742-B1 Thieno- and pyrrolopyrimidine analogues as anticancer agents and methods of use thereof UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) 2016-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257696-A1 THIENO- AND PYRROLOPYRIMIDINE ANALOGUES AS ANTICANCER AGENTS AND METHODS OF USE THEREOF TYMP, MKI67, TYMS CDK1 251/4885CCNB1 276/4885CDK2 93/4885
US-20170014415-A1 THIENO- AND PYRROLOPYRIMIDINE ANALOGUES AS ANTICANCER AGENTS AND METHODS OF USE THEREOF TYMP, MKI67, TYMS CDK1 251/4885CCNB1 276/4885CDK2 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.